Issue 10, 2014

Discovery of novel guanidinophenylpyrazole human acrosin inhibitors by molecular hybridization

Abstract

Human acrosin is a promising target for male contraceptives. A series of novel guanidinophenylpyrazole derivatives were rationally designed by molecular hybridization of the phenylpyrazole and guanidinobenzoate inhibitors. Most of the target compounds showed potent human acrosin inhibitory activities. In particular, compound F3 was a highly active human acrosin inhibitor (IC50 = 1.26 μM) with good selectivity over trypsin. Molecular docking studies revealed that compound F3 formed hydrophobic and hydrogen bonding interactions with the active site of human acrosin. Compound F3 represents a promising lead compound for the development of novel male contraceptives.

Graphical abstract: Discovery of novel guanidinophenylpyrazole human acrosin inhibitors by molecular hybridization

Supplementary files

Article information

Article type
Concise Article
Submitted
24 Apr 2014
Accepted
27 Jul 2014
First published
28 Jul 2014

Med. Chem. Commun., 2014,5, 1520-1527

Author version available

Discovery of novel guanidinophenylpyrazole human acrosin inhibitors by molecular hybridization

J. Zhao, N. Sun, Y. Gao, D. Lv, Y. Liu, Y. Jiang, G. Dong, Q. Chen, W. Li, Y. Zhou, J. Zhu, C. Sheng and J. Lv, Med. Chem. Commun., 2014, 5, 1520 DOI: 10.1039/C4MD00160E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements